Colin John Meyer - May 15, 2023 Form 4 Insider Report for REATA PHARMACEUTICALS INC (RETA)

Role
Chief Innovation Officer
Signature
/s/ Tracy Herson, attorney-in-fact
Stock symbol
RETA
Transactions as of
May 15, 2023
Transactions value $
-$527,063
Form type
4
Date filed
5/17/2023, 04:34 PM
Previous filing
Mar 8, 2023
Next filing
Jul 10, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RETA Class A common stock Sale -$379K -4.47K -5.28% $84.76 80.1K May 15, 2023 Direct F1, F2
transaction RETA Class A common stock Sale -$97.7K -1.14K -1.42% $85.77 79K May 15, 2023 Direct F1, F3
transaction RETA Class A common stock Sale -$50.6K -625 -0.79% $80.94 78.4K May 16, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $84.3884 to $85.085 The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $85.731 to $85.86. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.